Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia

Elena Pérez-Nadales1,2 | Belén Gutiérrez-Gutiérrez1,3 | Alejandra M. Natera1,2 | Edson Abdala4 | Maira Reina Magalhães4 | Alessandra Mularoni5 | Francesco Monaco5 | Ligia Camera Pierrotti6 | Maristela Pinheiro Freire6 | Ranganathan N. Iyer7 | Seema Mehta Steinke8 | Elisa Grazia Calvi9 | Mario Tumbarello10 | Marco Falcone11 | Mario Fernández-Ruiz12 | José María Costa-Mateo13 | Meenakshi M. Rana14 | Tania Mara Varejão Strabelli15 | Mical Paul16 | María Carmen Fariñas17 | Wanessa Trindade Clemente18 | Emmanuel Rolildes19 | Patricia Muñoz20,21 | Laurent Dewispelaere22 | Belén Loeches23 | Warren Lowman24 | Ban Hock Tan25 | Rosa Escudero-Sánchez1,26 | Marta Bodro27 | Paolo Antonio Grossi28 | Fabio Soldani29 | Filiz Gunseren30 | Nina Nestorova31 | Álvaro Pascual1,3 | Luis Martínez-Martínez1,32 | José María Aguado1,12 | Jesús Rodríguez-Baño1,3 | Julián Torre-Cisneros1,13 | REIPI/INCREMENT-SOT Investigators

1Spanish Network for Research in Infectious Diseases (REIPI), ISCIII, Spain
2Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain
3Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen Macarena/Departamento de Medicina, Universidad de Sevilla/Instituto de Biomedicina de Sevilla, Seville, Spain
4Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
5IRCCS ISMETT, Palermo, Italy
6Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil
7Global Hospitals, Hyderabad, India
8School of Medicine, Johns Hopkins University, Baltimore, Maryland
9ASST Papa Giovanni XXIII, Bergamo, Italy
10Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
11Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
12Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (imas12), Universidad Complutense, Madrid, Spain
13Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba, Universidad de Córdoba, Córdoba, Spain
14Icahn School of Medicine at Mount Sinai, New York, New York
15Heart Institute of São Paulo, University School of Medicine, São Paulo, Brazil

Abbreviations: Ac, accuracy; AUROC, area under the receiver operator curve; BSI, bloodstream infection; CART, Classification and Regression Tree; CI, confidence interval; CMV, cytomegalovirus; CPE, carbapenemase-producing Enterobacteriales; ESBL, extended-spectrum β-lactamase; HR, hazard ratio; ICU, intensive care unit; KPC, Klebsiella pneumoniae carbapenemase; NPV, negative predictive value; PPV, positive predictive value; Se, sensitivity; SOT, solid organ transplantation; Sp, specificity; TreeNet, Stochastic Gradient Boosting, Boosted Regression Tree Model.

Elena Pérez-Nadales and Belén Gutiérrez-Gutiérrez have contributed equally to this work.

Investigators listed in Acknowledgments.
Treatment of carbapenemase-producing Enterobacterales bloodstream infections in solid organ transplant recipients is challenging. The objective of this study was to develop a specific score to predict mortality in solid organ transplant recipients with carbapenemase-producing Enterobacterales bloodstream infections. A multinational, retrospective (2004-2016) cohort study (INCREMENT-SOT, ClinicalTrials.gov NCT02852902) was performed. The main outcome variable was 30-day all-cause mortality. The INCREMENT-SOT-CPE score was developed using logistic regression. The global cohort included 216 patients. The final logistic regression model included the following variables: INCREMENT-CPE mortality score ≥8 (8 points), no source control (3 points), inappropriate empirical therapy (2 points), cytomegalovirus disease (7 points), lymphopenia (4 points), and the interaction between INCREMENT-CPE score ≥8 and CMV disease (minus 7 points). This score showed an area under the receiver operating characteristic curve of 0.82 (95% confidence interval [CI] 0.76-0.88) and classified patients into 3 strata: 0-7 (low mortality), 8-11 (high mortality), and 12-17 (very-high mortality). We performed a stratified analysis of the effect of monotherapy vs combination therapy among 165 patients who received appropriate therapy. Monotherapy was associated with higher mortality only in the very-high (adjusted hazard ratio [HR] 2.82, 95% CI 1.13-7.06, P = .03) and high (HR 9.93, 95% CI 2.08-47.40, P = .004) mortality risk strata. A score-based algorithm is provided for therapy guidance.

**KEYWORDS**
antibiotic drug resistance, clinical research/practice, infection and infectious agents - bacterial, infectious disease, organ transplantation in general

1 | INTRODUCTION

Infections due to carbapenemase-producing Enterobacterales (CPE) are dramatically increasing worldwide.\(^1\) Numerous transplant centers have been affected by outbreaks and many suffer a subsequent endemic situation.\(^2,4\) The extreme difficulty of their treatment and the high mortality (30%-50%) associated with these infections explain their importance in the solid organ transplant (SOT) setting.\(^4,5\) Their epidemiology has been extensively studied and specific recommendations for infection control and clinical
management of these infections in SOT recipients have been published.\textsuperscript{5-8} Nevertheless, current recommendations are based on observational studies conducted in the general population,\textsuperscript{7-13} while the specific risk factors and clinical impact of infections due to CPE in SOT recipients remain to be elucidated. Large, multicenter studies, truly representative of the SOT patient population, are needed to develop risk-stratification tools to assist in guiding the management of these infections.

The objectives of this study were the following: (1) to validate the INCREMENT-CPE score to predict all-cause mortality of CPE bloodstream infections (CPE-BSI) in the SOT population; (2) to explore whether a new predictive score, INCREMENT-SOT CPE score, improves the predictive capacity, and (3) to check the utility of the new score to guide antibiotic therapy (monotherapy or combination) in different mortality risk groups.

2 | METHODS

2.1 | Study design and population

This report follows STROBE recommendations\textsuperscript{16} (Table S1). We conducted a retrospective (2004-2016), international (40 SOT centers in 16 countries) cohort study of consecutive cases of adult SOT recipients with clinically significant, monomicrobial bloodstream infections by carbapenemase and/or extended-spectrum-β-lactamase-producing Enterobacterales (INCREMENT-SOT Project; ClinicalTrials.gov identifier NCT02852902). In this work, we present the analysis of the CPE-BSI episodes from this cohort, which were submitted by 26 centers (12 countries) within the INCREMENT-SOT Consortium. The study was approved by the Spanish Agency for Medicines and Health Products (AEMPS, code FIB-COL-2015-01) and by the Hospital Universitario Reina Sofia Ethics Committee (code 2907). Exclusion criteria were unavailability of key data and death within 48 hours after the blood cultures were obtained.

2.2 | Variables and definitions

Clinically significant BSI was defined as the isolation of a carbapenemase-producing Enterobacterales in blood.\textsuperscript{15} Episodes were considered nosocomial if symptoms started later than 48 hours after hospital admission or within 48 hours of a previous hospital discharge. The main outcome variable was 30-day all-cause mortality. Independent variables included demographics and variables related to comorbidities: Charlson comorbidity index score,\textsuperscript{16} diabetes, chronic pulmonary disease, kidney disease, and McCabe classification, according to 3 categories: nonfatal (mild and only a few comorbidities), ultimately fatal (risk of death within 4 years or multiple comorbidities), and rapidly fatal (risk of death during stay, intensive or terminal care patients). SOT-related variables included time from transplant to bloodstream infection, basal and induction immunosuppression, and transplanted organ. Variables recorded in the 30 days previous to the BSI episode were: stay in an Intensive Care Unit (ICU), dialysis, acute rejection of the transplanted organ, cytomegalovirus (CMV) replication (any level of DNAemia), and CMV disease (presence of symptoms with evidence of CMV infection, including viral syndrome and organ disease), and trimethoprim/sulfamethoxazole prophylaxis. Variables recorded at the time of BSI onset included urinary stenosis (kidney), biliary stenosis (liver) and tracheal stenosis (lung), severity of acute condition at presentation according to Pitt bacteremia score,\textsuperscript{17} severity of systemic inflammatory response syndrome on day 0 (blood culture date),\textsuperscript{18} mental status (4 categories: alert, disoriented, stuporous, and comatose), lymphocyte source of infection according to clinical and microbiological data, source control and use of mechanical ventilation. Microbiological variables included Enterobacterales species, carbapenemase type, and antimicrobial susceptibility data. Finally, we recorded INCREMENT-CPE mortality risk score\textsuperscript{11,12} and the therapy administered (dates and doses of antibiotics). Empirical therapy was considered appropriate when an active drug was administered before the susceptibility profile. Targeted therapy was considered appropriate if it included an active drug and was administered within 5 days or earlier after the blood culture (day 0), and once the susceptibility profile was available. An active therapy was classified as monotherapy if it included 1 single active drug and as combined therapy if it included 2 or more active drugs. If the antibiotic regimen administered was changed, we considered that administered for ≤50% of the duration of therapy (for patients who died sooner than 48 hours after the start of therapy, 1 complete day of therapy was required). Meropenem and imipenem were considered active when MIC < 4 mg/L (monotherapy) or MIC 8-16 mg/L and administered in combination with ertapenem (monotherapy) or other active drugs (combination therapy). Tigecycline was not considered active for a urinary source. Variables were collected in a centralized electronic clinical research file. The database was curated and queries were sent to participating centers for missing or inconsistent data.

2.3 | Microbiological studies

The identification of microorganisms and susceptibility testing were performed at each participating center. The identification of microorganisms and susceptibility testing were performed at each participating center, using standard microbiological techniques. Susceptibility was studied using automated systems or disk diffusion at each local laboratory and interpreted using the 2015 Clinical & Laboratory Standards Institute (CLSI) break points.\textsuperscript{19} For isolates obtained before 2015, minimum inhibitory concentrations were reviewed and the susceptibility category was assigned accordingly; when the minimum inhibitory concentration (MIC) was not available or the available data had a MIC less than or equal to the older susceptibility break point, these were considered as susceptible if so reported by the local laboratory. Isolates were considered to be carbapenemase producers if a carbapenemase gene was detected by a molecular method.
2.4 | Statistical procedures

Continuous variables were compared using the Kruskal-Wallis test. Categorical variables were compared using the χ² test or Fisher exact tests. Survival distributions were compared using the log-rank test and were graphically displayed using Kaplan-Meier curves.

Validation of the INCREMENT-CPE score was performed by calculating the area under the receiver operating characteristic curve (AUROC) for observed data, the sensitivity (Se) and specificity.

Multivariable logistic regression was used to develop a new score. The original INCREMENT-CPE score (modified by excluding the variable “inappropriate empirical and early targeted therapy,” since we aimed to investigate different aspects of treatment for the new score) was dichotomized into 2 previously validated categories of risk (<8, low risk vs ≥8, high risk). To control for the site effect, we classified centers into low mortality-risk and high mortality-risk using TreeNet (Salford Predictive Modeller software) and considering all other variables (Figure S1). The study period (to control for changes in clinical management over time), the source of BSI and lymphocyte count were dichotomized by CART (Classification and Regression Tree, Salford Predictive Modeller Software; Table S2 and Figure S2). The variance inflation factor (VIF) value for every variable was calculated to control the influence of multicollinearity. We assumed lack of multicollinearity if all variables had a VIF value <2. The variable “high-mortality risk center” was included in the analysis to obtain a predictive model for which this effect was controlled but was not considered for the score. Potential interactions between variables were explored using TreeNet and those selected were included in the models. Variables with a P ≤ .20 in the final models were selected for the assignment of a score, provided their inclusion significantly improved the predictive capacity of the model. A weighted score for each variable was calculated dividing each regression coefficient by one-half of the smallest coefficient and rounding to the nearest integer. The prediction ability of a model was examined by calculating its AUROC with a 95% CI; Se, specificity, positive predictive value (PPV), negative predictive value (NVP), and accuracy (Ac) were calculated for different breakpoints.

Sensitivity analysis for the INCREMENT-SOT-CPE score was performed using Salford Predictive Modeller Software to check the robustness of its predictive ability. Fifteen subgroups of the cohort with a 20% sample size were randomly extracted (43 cases per subgroup), and the AUROC of the score to predict 30-day all-cause mortality was calculated for each subgroup. A minimum, maximum, and median value of AUROC was obtained. The process was repeated another 7 times, extracting 15 subgroups with sample sizes ranging 30% to 90% (10% intervals, thus obtaining 8 average AUROCs, maximum, and minimum values).

For the analysis of the association of monotherapy vs combination therapy with mortality, a propensity score for receiving combination therapy was calculated using a nonparsimonious logistic regression model. The impact of combination therapy was studied by Cox-Regression, adjusting by propensity score and other potential confounders, after checking for collinearity.

The analyses were carried out using R software (version 3.0.1), SPSS 25.0 (SPSS Inc), and Salford Predictive Modeller software 8.2 (includes CART and TreeNet).

3 | RESULTS

3.1 | Cohort features and validation of the INCREMENT-CPE mortality score (objective I)

Among 228 patients included, 216 fulfilled inclusion criteria (Figure 1). Their characteristics are shown in Table 1. Most patients were men (75%), with a median (interquartile range) age of 56 years (46-63). The most common types of transplant were liver (56%), including liver-other organs) and kidney (35%, including kidney-pancreas). Episodes occurred in the first month posttransplant in 45% of patients. The most common basal immunosuppression regimens included tacrolimus (85%), mycophenolic acid/mycophenolate (58%), and corticosteroids (83%). Forty-three percent of patients received induction of immunosuppression with thymoglobulin (21%) or basiliximab (22%). In the previous 30 days, 24% suffered CMV replication and 8% CMV disease. Lymphopenia was observed in 47% of cases. The most common sources of bloodstream infections were intraabdominal (21%), urinary tract (20%), biliary tract (18%), catheters (13%), and lung (10%). The most common organism involved was Klebsiella pneumoniae (83%) and the most common types of carbapenemases were Klebsiella pneumoniae carbapenemase (KPC) (66%) and oxacillinase-48 (23%). Regarding treatment regimens, inappropriate empirical therapy was administered in 21% (45/216) of patients and appropriate targeted therapy in 88% (190/216), either monotherapy (118 patients) or combination therapy (72 patients). Thirty-day all-cause mortality was 37% (79/216; 95% CI, 31%-43%). Significant differences between types of SOT were observed in a number of variables, including Charlson index, chronic pulmonary disease, kidney disease, McCabe score, CMV replication, induction of immunosuppression, urinary and biliary stenosis, Pitt score, source of infection, administration of appropriate empirical therapy, and INCREMENT-CPE score (Table 1).

The predictive value of the INCREMENT-CPE mortality score was studied. We found that this score was associated with 30-day all-cause mortality (odds ratio, 1.40 per unit; 95% CI, 1.27-1.56; P < .001), showing an AUROC of 0.78 (95% CI, 0.71-0.85). The Se, Sp, PPV, NVP, and Ac values for different breakpoints of each INCREMENT-CPE score and the proportion of patients are shown in Table S3. For an INCREMENT-CPE score value ≥8, previously validated as a cut-off value predictive for low vs high mortality in non-SOT patients, the calculated NPV and PPV in the SOT cohort were 84.7% and 50.4%, respectively.

3.2 | Development of the new INCREMENT-SOT-CPE mortality score (objective II)

We explored SOT-related variables that could improve the predictive capacity of the INCREMENT-CPE score in our population.
Variables associated with 30-day mortality in the final model were: INCREMENT-CPE score ≥8 (excluding the variable about therapy from this score), CMV disease in the previous 30 days, lymphocytes ≤600 units per mm³, and lack of source control (Table 2); the interaction between CMV disease and INCREMENT-CPE score ≥8 was negative and with a similar (but negative) β coefficient as CMV disease, indicating that CMV disease does not further increase the risk of death if the INCREMENT-CPE-score is ≥8, but do so only if the score is <8 (Figure S3). The variable inappropriate empirical therapy was kept in the final model since its inclusion improved the predictive capacity. None of the final variables included in the multivariate model showed multicollinearity (VIF ≤ 1.06, Table S4). The AUROC of the resulting logistic regression model was 0.84 (95% CI, 0.78-0.89). The score assigned to each variable according to its beta regression coefficient is shown in Table 3. The sensitivity analysis (see Methods for details) confirmed the robustness of the model; the minimum value of the AUROCs for all subcohorts was always >0.70 and the average AUROC value was >0.80 (Figure S4).

### 3.3 Utility of the new score to guide antibiotic therapy. Impact of monotherapy vs combined therapy on 30-day all-cause mortality (objective III)

We analyzed 165 patients who received appropriate targeted treatment (treatment cohort, Figure 1). Thirty-day all-cause mortality was 15.7% (11/70) in patients receiving combined therapy vs 43.1% (41/95, \( P < .001 \)) in patients receiving monotherapy. Mortality associated with each type of treatment in the different mortality risk groups, as defined by INCREMENT-SOT-CPE score (previous section, objective I). We also developed an alternative model including variables independently of the INCREMENT-CPE score; nevertheless, the resulting model showed a lower predictive capacity than our INCREMENT-CPE score-based model (AUROC = 0.79, 95% CI 0.73-0.85).

The sensitivity, specificity, PPV, NPV, and accuracy for different breakpoints of the new INCREMENT-SOT-CPE score and the proportion of patients are shown in Table S5. The NPV and PPV for a score value ≥8 were 89.4% and 53.4%, respectively; and for a score ≥12, NPV and PPV were 78.8% and 72.3%, respectively. A classification into low (score 0-7), high (score 8-11), and very-high (score 12-17) mortality was developed, with mortality rates of 11.4% (10/87), 35.3% (23/65), and 71.8% (46/64), respectively (Table S6). The sensitivity analysis (see Methods for details) confirmed the robustness of the model; the minimum value of the AUROCs for all subcohorts was always >0.70 and the average AUROC value was >0.80 (Figure S4).
**TABLE 1** Characteristics of solid organ transplant patients with bloodstream infections caused by carbapenemase-producing Enterobacterales included in the INCREMENT-SOT cohort, according to the transplanted organ

| Transplanted solid organ          | Global (N = 216) | Liver (N = 120) | Kidney (N = 75) | Heart (N = 13) | Lung (N = 6) | Multiorgan (N = 2) | P value |
|----------------------------------|------------------|----------------|----------------|----------------|--------------|-------------------|---------|
| **Age, median (IQR)**           | 56 (46-63)       | 55 (46-63)     | 57 (46-64)     | 56 (40-60)     | 48 (35-62)   | 62 (52)           | .58b    |
| **Sex (male)**                   | 162 (75)         | 92 (77)        | 56 (75)        | 8 (62)         | 4 (67)       | 2 (100)           | .68     |
| **Charlson index, median (IQR)** | 5 (3-7)          | 5 (4-7)        | 5 (3-6)        | 4 (5-7)        | 2 (1-5)      | 6 (5)             | .01b    |
| **Diabetes**                     | 87 (40)          | 46 (38)        | 35 (47)        | 4 (31)         | 2 (33)       | 0                 | .49     |
| **Chronic pulmonary disease**    | 15 (7)           | 3 (3)          | 6 (8)          | 1 (8)          | 5 (83)       | 0                 | <.001   |
| **Kidney disease**               | 120 (56)         | 37 (33)        | 64 (85)        | 8 (62)         | 1 (17)       | 2 (100)           | <.001   |
| **McCabe score**                 |                 |                |                |                |              |                   | <.001   |
| **Nonfatal disease**             | 53 (25)          | 22 (18)        | 25 (33)        | 5 (39)         | 1 (17)       | 0                 | –       |
| **Rapidly fatal disease**        | 47 (22)          | 36 (30)        | 4 (5)          | 6 (46)         | 1 (17)       | 0                 | –       |
| **Ultimately fatal disease**     | 115 (53)         | 61 (51)        | 46 (61)        | 2 (15)         | 4 (67)       | 2 (100)           | –       |
| **Days from transplant to bloodstream infection** |                 |                |                |                |              |                   | .10     |
| ≤30 d                            | 97 (45)          | 63 (53)        | 24 (32)        | 6 (46)         | 3 (50)       | 1 (50)            | –       |
| 31-180 d                         | 75 (35)          | 37 (31)        | 32 (43)        | 5 (39)         | 0            | 1 (50)            | –       |
| ≥181 d                           | 44 (20)          | 20 (17)        | 19 (25)        | 2 (15)         | 3 (50)       | 0                 | –       |
| **Basal immunosuppression**      |                 |                |                |                |              |                   |         |
| **Cyclosporine**                 | 17 (8)           | 5 (4)          | 8 (11)         | 3 (23)         | 1 (17)       | 0                 | .09     |
| **Tacrolimus**                   | 183 (85)         | 109 (91)       | 60 (80)        | 8 (62)         | 4 (67)       | 1 (50)            | .01     |
| **Mycofenolic acid/Mycophenolate** | 125 (58)   | 54 (45)        | 57 (76)        | 10 (77)        | 2 (33)       | 2 (100)           | <.001   |
| **Corticosteroids**              | 180 (83)         | 90 (75)        | 69 (92)        | 13 (100)       | 6 (100)      | 2 (100)           | .006    |
| **Azathioprine**                 | 6 (3)            | 3 (4)          | 1 (8)          | 2 (33)         | 0            | 0                 | <.001   |
| **Everolimus**                   | 11 (5)           | 7 (6)          | 3 (4)          | 0             | 1 (17)       | 0                 | .49c    |
| **Siofolimus**                   | 2 (1)            | 1 (1)          | 1 (1)          | 0             | 0            | 0                 | 1c      |
| **Induction of immunosuppression** | 92 (43) | 26 (22)        | 55 (73)        | 5 (39)         | 5 (83)       | 1 (50)            | <.001   |
| **Thymoglobulin**                | 46 (21)          | 6 (5)          | 36 (48)        | 2 (15)         | 2 (33)       | 0                 | <.001   |
| **Basiliximab**                  | 47 (22)          | 20 (17)        | 20 (27)        | 3 (23)         | 3 (50)       | 1 (50)            | .16     |
| **Nosocomial acquisition**       | 180 (83)         | 102 (85)       | 57 (76)        | 13 (100)       | 6 (100)      | 2 (100)           | .12     |
| **ICU stay (previous 30 d)**     | 149 (69)         | 92 (77)        | 37 (49)        | 12 (92)        | 6 (100)      | 2 (100)           | <.001   |
| **Dialysis (previous 30 d)**     | 79 (36)          | 37 (31)        | 31 (41)        | 8 (62)         | 2 (33)       | 1 (50)            | <.001   |
| **Acute rejection (previous 30 d)** | 21 (10) | 7 (6)          | 8 (11)         | 5 (39)         | 1 (17)       | 0                 | .005    |
| **CMV disease (previous 30 d)**  | 17 (8)           | 7 (6)          | 7 (9)          | 3 (23)         | 0            | 0                 | .22     |
| **CMV replication (previous 30 d)** | 52 (24) | 30 (25)        | 13 (17)        | 9 (69)         | 0            | 0                 | <.001   |
| **TMP/SMX prophylaxis (previous 30 d)** | 119 (55) | 62 (52)        | 43 (57.3)      | 8 (61.5)       | 4 (66.7)     | 2 (100)           | .58     |
| **Urinary stenosis (kidney)**    | 11 (5)           | 0              | 11 (15)        | 0             | 0            | 0                 | <.001   |
| **Biliary stenosis (liver)**     | 33 (15)          | 33 (28)        | 0             | 0             | 0            | 0                 | <.001   |
| **Tracheal stenosis (lung)**     | 1 (1)            | 0              | 0             | 1 (17)         | 0            | 0                 | .04c    |
| **Pitt score**                   | 3 (1-6)          | 4 (1-6)        | 1 (0-4)        | 6 (2-11)       | 5 (3-9)      | 3                 | <.001   |
| **Systemic inflammatory response syndrome** |           |                |                |                |              |                   | .004    |
| **Sepsis**                       | 99 (46)          | 47 (39)        | 45 (60)        | 4 (31)         | 3 (50)       | 0                 | –       |
| **Severe sepsis**                | 54 (25)          | 36 (30)        | 9 (12)         | 3 (23)         | 3 (50)       | 2 (100)           | –       |
| **Shock**                        | 63 (29)          | 37 (31)        | 21 (28)        | 6 (46)         | 0            | 0                 | –       |

(Continues)
### TABLE 1 (Continued)

| Transplanted solid organ | Global (N = 216) | Liver (N = 120) | Kidney (N = 75) | Heart (N = 13) | Lung (N = 6) | Multiorgan (N = 2) | P value |
|--------------------------|------------------|----------------|----------------|----------------|-------------|-------------------|---------|
| Mental status            |                  |                |                |                |             |                   |         |
| Alert                    | 81 (38)          | 36 (30)        | 40 (53)        | 4 (31)         | 1 (17)      | 0                 | .02     |
| Disoriented              | 58 (27)          | 34 (28)        | 17 (21)        | 2 (15)         | 3 (50)      | 2 (100)           |        |
| Stuporous                | 31 (14)          | 20 (17)        | 7 (9)          | 3 (23)         | 1 (17)      | 0                 |        |
| Comatose                 | 35 (16)          | 24 (20)        | 6 (8)          | 4 (31)         | 1 (17)      | 0                 |        |
| Lymphocytes <600/mm³     | 101 (47)         | 56 (47)        | 35 (47)        | 7 (54)         | 3 (50)      | 0                 | .73     |
| Source of infection      |                  |                |                |                |             |                   | <.001   |
| Intraabdominal           | 46 (21)          | 36 (30)        | 8 (11)         | 1 (8)          | 0           | 1 (50)            |        |
| Urinary tract            | 44 (20)          | 4 (3)          | 39 (52)        | 1 (8)          | 0           | 0                 |        |
| Biliary tract            | 38 (18)          | 38 (32)        | 0              | 0              | 0           | 0                 |        |
| Vascular access          | 28 (13)          | 12 (10)        | 12 (16)        | 4 (31)         | 0           | 0                 |        |
| Pneumonia                | 21 (10)          | 6 (5)          | 6 (8)          | 3 (23)         | 6 (100)     | 0                 |        |
| Skin and soft tissue     | 5 (2)            | 0              | 4 (5)          | 0              | 0           | 1 (50)            |        |
| Other                    | 16 (7)           | 15 (13)        | 1 (1)          | 0              | 0           | 0                 |        |
| Unknown                  | 18 (8)           | 9 (8)          | 5 (7)          | 4 (31)         | 0           | 0                 |        |
| No source control        | 55 (26)          | 29 (24)        | 23 (31)        | 1 (8)          | 2 (33)      | 0                 | .38     |
| Mechanical ventilation   | 92 (43)          | 57 (48)        | 20 (27)        | 9 (69)         | 5 (83)      | 0                 | .001    |
| Enterobacterales         |                  |                |                |                |             |                   | .05     |
| Klebsiella sp.           | 180 (83)         | 99 (83)        | 64 (86)        | 11 (85)        | 5 (83)      | 1 (50)            |        |
| Enterobacter sp.         | 16 (7)           | 8 (7)          | 6 (8)          | 1 (8)          | 0           | 0                 |        |
| Escherichia coli         | 15 (7)           | 10 (8.3)       | 4 (5)          | 0              | 1 (17)      | 0                 |        |
| Morganella morganii      | 1 (0.5)          | 1 (1)          | 0              | 0              | 0           | 0                 |        |
| Serratia sp.            | 4 (2)            | 2 (2)          | 1 (1)          | 1 (8)          | 0           | 1 (50)            |        |
| Type of carbapenemase    |                  |                |                |                |             |                   | .29     |
| KPC                      | 143 (66)         | 79 (66)        | 51 (68)        | 8 (62)         | 4 (67)      | 1 (50)            |        |
| OXA-48                   | 50 (23)          | 31 (26)        | 15 (20)        | 4 (31)         | 0           | 0                 |        |
| Other                    | 23 (11)          | 10 (8)         | 9 (12)         | 1 (8)          | 2 (33)      | 1 (50)            |        |
| INCRED-CTP score<sup>a</sup>, median (IQR) | 8 (6-12)       | 11 (6-12)  | 6 (3-11)  | 13 (7-15)  | 11 (4-15)  | 11 (11-11)        | .005<sup>b</sup> |
| Inappropriate empirical therapy | 45 (21)       | 24 (20)        | 18 (24)        | 2 (15)         | 1 (17)      | 0                 | .86     |
| Targeted therapy         |                  |                |                |                |             |                   | .64     |
| Appropriate monotherapy  | 118 (55)         | 66 (55)        | 44 (59)        | 5 (39)         | 3 (50)      | 0                 |        |
| Appropriate combination therapy | 72 (33)  | 39 (33)        | 23 (31)        | 6 (46)         | 2 (33)      | 2 (100)           |        |
| Inappropriate            | 26 (12)          | 15 (13)        | 8 (11)         | 2 (15)         | 1 (17)      | 0                 |        |
| Cure/improvement at day 14 | 122 (57)     | 67 (56)        | 47 (63)        | 4 (31)         | 2 (33)      | 2 (100)           | .11     |
| Mortality at day 30      | 79 (37)          | 47 (39)        | 21 (28)        | 8 (65)         | 3 (50)      | 0                 | .10     |

Data are number of patients (percentage), except where specified. P values represent global differences among the 5 types of solid organ transplant and were obtained by χ² test, except when otherwise stated.

CMV, cytomegalovirus; ICU, intensive care unit; IQR, interquartile range; KPC, Klebsiella pneumoniae carbapenemase; OXA, oxacillinase; SOT, solid organ transplantation; TMP/SMX, trimethoprim/sulfamethoxazole.

<sup>a</sup>The INCRED-CTP mortality score included: severe sepsis or shock at presentation (5 points), Pitt bacteremia score ≥ 6 (4 points), Charlson index ≥ 2 (3 points), source of bloodstream other than urinary or biliary tracts (3 points) and receiving inappropriate empirical and early targeted therapy (2 points).

<sup>b</sup>Kruskal-Wallis test.

<sup>c</sup>Fisher test.
| Variable | Crude analysis |Adjusted analysis<sup>a,c</sup> |
|---|---|---|
| | OR (95% CI) | P value | OR (95% CI) | P value |
| Age (per unit) | 0.99 (0.97-1.01) | .36 | — | — |
| Male gender | 1.08 (0.57-2.09) | .81 | — | — |
| Klebsiella sp. | 1.77 (0.83-4.04) | .15 | — | — |
| Carbapenemase | — | — | — | — |
| Carbapenemase + ESBL | 0.71 (0.35-1.42) | .33 | — | — |
| OXA-type carbapenemase | 1.07 (0.56-2.01) | .84 | — | — |
| Nosocomial acquisition | 1.61 (0.75-3.70) | .23 | — | — |
| ICU admission | 4.92 (2.42-10.89) | <.0001 | — | — |
| Mechanical ventilation | 7.48 (4.04-14.30) | <.0001 | — | — |
| Mental status, not alert | 17.6 (6.80-51.18) | <.0001 | — | — |
| Chronic kidney disease | 1.01 (0.58-1.77) | .97 | — | — |
| Chronic pulmonary disease | 2.09 (0.72-6.19) | .17 | — | — |
| Septic shock | 8.68 (4.06-16.90) | <.0001 | — | — |
| Severe liver disease | 1.70 (0.92-3.15) | .09 | — | — |
| Any tumor | 1.51 (0.61-3.68) | .36 | — | — |
| Charlson index, per unit | 1.08 (0.95-1.22) | .20 | — | — |
| Pitt score, per unit | 1.55 (1.38-1.75) | <.0001 | — | — |
| Days from transplant to positive blood culture | — | — | — | — |
| ≤30 d | Reference | — | — | — |
| 31-180 d | 0.46 (0.24-0.90) | .02 | — | — |
| ≥181 d | 1.04 (0.51-2.13) | .92 | — | — |
| Type of SOT | — | — | — | — |
| Kidney (including kidney-pancreas) | Reference | — | — | — |
| Liver including (liver-kidney, liver-pancreas, and multivisceral) | 1.61 (0.87-3.00) | .13 | — | — |
| Others (lung and heart) | 3.54 (1.25-10.01) | .17 | — | — |
| Source of infection in SOT | — | — | — | — |
| High risk (pneumonia and others) | Reference | — | — | — |
| Low risk (rest of sources) | 0.36 (0.17-0.75) | .006 | — | — |
| Biliary stenosis | 0.84 (0.37-1.82) | .67 | — | — |
| Previous dialysis | 1.33 (0.75-2.36) | .33 | — | — |
| INCREMENT-CPE mortality score ≥8<sup>a</sup> | 6.72 (3.52-13.55) | <.0001 | 13.74 (6.00-35.07) | <.0001 |
| CMV disease within 30 d before HC | 2.69 (1.00-7.71) | .05 | 10.87 (1.79-77.06) | .01 |
| Lymphocytes ≤600 U/mm<sup>3</sup> | 0.96 (0.91-0.99) | .03 | 3.46 (1.73-7.16) | .0006 |
| No source control | 2.00 (1.09-3.85) | .03 | 2.66 (1.18-6.22) | .02 |
| Inappropriate empirical therapy | 1.92 (0.99-3.70) | .06 | 1.89 (0.77-4.26) | .18 |
| High-mortality risk center | 3.10 (1.75-5.56) | .0001 | 3.72 (1.83-7.82) | .0004 |
| Study period 2007-2010 (reference: 2011-2016) | 1.91 (0.87-4.17) | .10 | — | — |
| Interaction INCREMENT-CPE mortality score ≥8 × CMV disease | 0.76 (0.63-0.93) | .007 | 0.09 (0.007-0.90) | .04 |

Cl, confidence interval; CMV, cytomegalovirus; ESBL, extended-spectrum β-lactamase; ICU, intensive care unit; SOT, solid organ transplant; OR, odds ratio; OXA, oxacillinase.

<sup>a</sup>The INCREMENT-CPE mortality score included the following variables: severe sepsis or shock at presentation (5 points), Pitt bacteremia score ≥6 (4 points), Charlson index ≥2 (3 points), and source of bloodstream infection other than urinary or biliary tracts (3).

<sup>b</sup>Variables with a univariate P ≤ .2 for mortality were included. The interactions studied are specified in Results.

<sup>c</sup>Lack of multicollinearity in the multivariate model was assessed with the variance inflation factor (VIF), which was ≤1.06 for all variables included (Table S4).
Our INCREMENT-SOT cohort was 36.6%, higher than in the pre-CPE era. Worsening the prognosis of CPE-BSI. Thirty-day all-cause mortality in our results indicate that being a recipient of SOT does not seem to worsen the prognosis of CPE-BSI. Thirty-day all-cause mortality in our INCREMENT-SOT cohort was 36.6%, higher than in the pre-CPE era and similar to that previously reported in other series in SOT. Some studies and a meta-analysis have reported a higher mortality (>40%) when CPE-BSI is caused by K pneumoniae. In our study, the type of Enterobacteriales was not associated with mortality in the analysis after adjusting by other exposures, as previously observed.

4 | DISCUSSION

The development of the new INCREMENT-SOT-CPE score was based on the INCREMENT-CPE score, which had been previously validated in the general population in different studies. We used this strategy because there are no specific studies in SOT and many transplant groups use this predictive model, which takes into account variables important in any type of patient with BSI, including SOT. Besides, the inclusion of this general model in our new score reinforces the utility of the new model in posttransplant periods, such as the postoperative period, when the full impact of immunosuppression—derived from prolonged exposure to suppressive therapies—is still absent. Finally, an alternative model including individual variables—transplant and nontransplant—instead of the INCREMENT-CPE score, showed a lower predictive capacity and was thus not considered.

We additionally studied the impact of specific transplant variables that complemented the INCREMENT-CPE score on the prognosis of this type of infections in SOT patients. Thus, our results indicate that the predictive capacity of the INCREMENT-CPE score can be improved when it is combined with other mortality predictors such as source control, appropriate empirical therapy, and variables related to immunosuppression, ie, lymphopenia and CMV disease. The application of these additional predictors is very important in patients with INCREMENT-CPE score <8, when the score can be applied to indicate monotherapy or combined therapy (Figure 2).

It is obvious that an adequate control of the source and an appropriate empirical treatment can improve the prognosis of the bacterial infection. Lymphopenia can be a surrogate marker of over-immunosuppression. Nevertheless, some experts believe that a reduction in immunosuppression may lead to higher mortality by increasing the capacity of the immune system to induce a systemic inflammatory response. CMV is an immunomodulatory virus that can favor bacterial infections. Theoretically, CMV prevention could reduce this increased risk, although recent consensus does not recommend CMV prophylaxis in the scenario of solid organ transplantation. This is further complicated by the fact that sepsis may increase CMV reactivation. Our results suggest that CMV disease increases mortality in SOT recipients with CPE-BSI, although CMV disease may also be a mere marker of the net-state of over-immunosuppression, which would be ultimately associated with all-cause mortality. Interestingly, the data from our study suggest that CMV disease does not increase the risk of death further in SOT recipients with a high underlying risk of death, as measured by the INCREMENT-CPE score, but only in patients with a lower underlying risk. Unfortunately, data on CMV prophylaxis was not collected in this study, but our results open the door to further research about whether prevention of CMV may be beneficial in SOT recipients colonized by CPE in order to improve their outcomes in case of an invasive infection due to these bacteria.

Our study has the limitations of retrospective studies, despite applying a rigorous definitions and statistical analyses to control biases. A second limitation is that we have analyzed patients not treated with the newly available drugs (ie, ceftazidime-avibactam or meropenem-vaborbactam). The impact of the new drugs on the

### Table 3

| Variable | Regression beta coefficients (95% CI) | Score |
|----------|--------------------------------------|-------|
| INCREMENT-CPE score ≥8 | 2.62 (1.79 to 3.56) | 8 |
| Cytomegalovirus disease in the previous 30 d | 2.08 (0.58 to 4.34) | 7 |
| Lymphocytes ≤600 mm³ | 1.24 (0.55 to 1.97) | 4 |
| No source control | 0.98 (0.17 to 1.83) | 3 |
| Inappropriate empirical therapy | 0.64 (-0.26 to 1.45) | 2 |
| Interaction INCREMENT-CPE score ≥8 ° Cytomegalovirus disease in the previous 30 d | -2.39 (-4.90 to -0.10) | -7 |

CI, confidence interval; CPE, carbapenemase-producing Enterobacterales; SOT, solid organ transplantation.

°The negative interaction coefficient means that the effect of the combined action of 2 predictors is less than the sum of the individual effects. Consequently, in our model, the maximum score in a patient with all risk factors would be 17 (INCREMENT-CPE score ≥8 [+8], cytomegalovirus disease [+7], lymphopenia [+4], no source control [+3], inappropriate empirical therapy [+2], and interaction INCREMENT-CPE score ≥8 with CMV [-7]).

3.4 | Proposed algorithm for clinical practice

In order to apply these results to the clinical management of SOT patients with CPE-BSI, we propose an algorithm that requires calculation of INCREMENT-CPE score and identification of the number and type of risk factors present, without having to expressly calculate the new score (Figure 2). According to this algorithm, 86/165 (52.1%) patients in the therapy cohort received inadequate antibiotic therapy. Specifically, 57/165 (34.5%) of the patients who received monotherapy should have been treated with combined therapy. These patients had a 30-day mortality rate of 53.4% (31/57). On the other side, 29/165 (17.6%) of the patients who received combined therapy should have received monotherapy. The mortality rate in this second group was 6.9% (2/29): An expanded version of the algorithm, including the stratification of the risk of mortality, based on the INCREMENT-SOT score, is provided in Figure S6.
applicability of risk scores to decision making will certainly need to be investigated, as it is not known if combination therapy would be needed in high-risk patients when the newer drugs are used, or if the new drugs are more effective in low-risk patients. However, it is important to bear in mind that accessibility to the new drugs is still limited in numerous countries, and therefore well-conducted

| Patient group                                           | Variables                  | HR (95% CI)    | P value |
|---------------------------------------------------------|----------------------------|----------------|---------|
| Global cohort receiving appropriate targeted treatment\(^a\) (N = 165; 95 monotherapy, 70 combined) | Monotherapy                | 3.68 (1.83-7.40) | <.001   |
|                                                         | Propensity score\(^b\)    | 0.70 (0.12-4.19) | .70     |
|                                                         | High risk center          | 2.37 (1.37-4.10) | .002    |
|                                                        | INCREMENT-SOT-CPE score   |                |         |
|                                                         | Low risk                  | Reference      |         |
|                                                        | High risk                 | 5.13 (2.02-13.05) | .001   |
|                                                        | Very high risk            | 12.54 (5.45-28.87) | <.001   |
| Very high-risk patients (N = 44; 30 monotherapy, 14 combined) | Monotherapy                | 2.82 (1.13-7.06) | .03     |
|                                                         | Propensity score\(^b\)    | 0.48 (0.05-4.67) | .53     |
|                                                         | High risk center          | 1.23 (0.59-2.55) | .58     |
| High-risk patients (N = 47; 20 monotherapy, 27 combined) | Monotherapy                | 9.93 (2.08-47.40) | .004    |
|                                                         | Propensity score\(^b\)    | 0.41 (0.004-45.42) | .71    |
|                                                         | High risk center          | 4.52 (1.38-14.79) | .01     |
| Low-risk patients (N = 74; 45 monotherapy, 29 combined)  | Monotherapy                | 1.69 (0.32-8.89) | .54     |
|                                                         | Propensity score\(^b\)    | 2.76 (0.02-316.64) | .68    |
|                                                         | High risk center          | 12.68 (1.50-107.49) | .02    |

CI, confidence interval; CPE, carbapenemase-producing Enterobacterales; HR, hazard ratio; SOT, solid organ transplantation.

\(^a\)All variables exhibited a variance inflation factor (VIF) <1.7. The model showed an area under the receiver operating characteristic curve of 0.73. Antimicrobials administered as monotherapy or combined therapy, both in the global cohort and in the three INCREMENT-SOT-CPE mortality risk groups, and their related mortality are shown in Table S8.

\(^b\)The variables used to calculate the propensity score for combination therapy were center, period, age, sex, acquisition, hospital service, days from transplant to blood culture, type of solid organ transplantation (SOT), systemic inflammatory response syndrome (SIRS), Charlson index, Pitt score, source of infection, lymphocytes count, source control, CMV disease, kidney disease, diabetes, dialysis (previous 30 days), myocardial infarct, type of enzyme, type of carbapenemase, antibiogram showing resistance to group 2 carbapenems, gentamicin, and/or ciprofloxacin.

\*Risk factors:
- Lymphopenia
- No source control
- Inappropriate empirical therapy

**FIGURE 2** Algorithm for clinical management of solid organ transplantation (SOT) patients with bloodstream infection due to carbapenemase-producing Enterobacterales (CPE-BSI), based on INCREMENT-SOT-CPE mortality risk score. CMV, cytomegalovirus. \*Risk factors for INCREMENT-SOT-CPE score: cytomegalovirus (CMV) disease during the last 30 days; lymphopenia (< 600 lymphocytes/mm\(^3\)) at BSI onset, no source control and inappropriate empirical therapy (in the first 3 days after blood culture). CPE-BSI, bloodstream infection due to carbapenemase-producing Enterobacterales; SOT, solid organ transplant
observational studies in the SOT population treated with the "classic" drugs will still be relevant in many areas. Another limitation is that the sample size of our cohort precluded the selection of derivation and validation subcohorts (see reference 12). The sensitivity analysis confirmed the internal robustness of our model; nevertheless, an external validation in a prospective cohort would be desirable. Finally, KPC carbapenemase may be overrepresented in our cohort, as compared to other carbapenemases.

To conclude, in transplant centers with outbreaks or endemia by CPE, identification of colonized patients is important so that empirical treatment with CPE coverage can be readily administered in case of BSI development. In this study, we have identified transplant-related variables specifically associated with the risk of mortality in SOT recipients with CPE-BSI. We expect this will help to identify patients at high risk of death and allow a more personalized clinical management (ie, prevention of cytomegalovirus disease and the judicious use of immunosuppression in order to avoid lymphopenia).

ACKNOWLEDGMENTS
We acknowledge the work of the following REIPI/INCREMENT-SOT investigators: A. T. Wan Song, W. Andraus, L. A. Carneiro D’Albuquerque (Faculdade de Medicina da Universidade de São Paulo, Brazil); E. David-Neto, F. Jota de Paula (Renal Transplantation Unit, Department of Urology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil); F. Rossi (Department of Microbiology, Division of Central Laboratory, Hospital das Clinicas Complex, University of São Paulo Medical School, São Paulo, Brazil); D. Ostrander, R. Avery (Johns Hopkins University, School of Medicine, Division of Infectious Diseases); M. Rizzi (Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy); A. R. Losito, F. Raffaelli, P. Del Giacomo (Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy); G. Tiseo (Policlinico Umberto I, Rome, Italy); J. Lora-Tamayo, R. San-Juan (Unit of Infectious Diseases, Hospital Universitario “12 de Octubre,” Instituto de Investigación Hospital “12 de Octubre”, Universidad Complutense, Madrid, Spain); I. Gracia-Ahufering, J. Castón, Y. A. Ruiz (Hospital Universitario Reina Sofia, Instituto Maimónides de Investigación Biomédica de Córdoba, Universidad de Córdoba, Córdoba, Spain); D. R. Altman (Icahn School of Medicine at Mount Sinai, New York, USA); S. V. Campos (Heart Institute of São Paulo University School of Medicine, Brazil); N. Bar Sinai (Faculty of Medicine, Technion – Israel Faculty of Technology, Haifa, Israel); F. Koppel (Infectious Diseases Institute, Rambam Health Care Campus, Haifa, Israel); F. Arnaiz de las Revillas Almajano, C. González Rico (Infectious Diseases Unit, Marqués de Valdecilla University Hospital, Spain); M. Fernández Martínez (Microbiology Service, Marqués de Valdecilla University Hospital, Spain); P. H. O. Mourão, F. A. Neves, J. Ferreira (Infection Control and Hospital Epidemiology, Hospital das Clinicas - Federal University of Minas Gerais, Brazil); A. Pyrpasopoulou, E. Iosifidis, I. Romiopoulos (Infectious Diseases Unit, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece); M. V. Minero, C. Sánchez-Carrillo (Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain); S. Lardo (Istituto Nazionale Malattie Infettive L. Spallanzani, IRCCS- Roma, Italy); J. Coussement, M. Dodémont (Department of Microbiology, CUB-Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium); K. Jiayun (Department of Infectious Diseases, Singapore General Hospital, Singapore); P. Martín-Dávila, J. Fortún (Ramón y Cajal University Hospital, Madrid); M. Almela, A. Moreno, L. Linares (Hospital Clinic – IDIBAPS, University of Barcelona, Barcelona, Spain); D. D. Gasperina, M. L. Balsamo, C. Rovelli (University of Insubria, Italy); E. Concia, S. Chiesi, D. N. Salerno (Department of Medicine, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Italy); D. Ogunc (Akdeniz University Hospital, Department of Clinical Microbiology, Antalya, Turkey); B. Pilmis (Hôpital Neck er-Enfants Malades, Université Paris Descartes, Hôpital Neck er-Enfants Malades, Université Paris Descartes, Paris, France); E. M. Seminari (Fondazione IRCCS Policlinico San Matteo, Pavia, Italy); J. Carratalá and A. Domínguez (Hospital Universitario Bellvitge Barcelona, Spain); E. Cordero and J. A. Lepe (Hospital Universitario Virgen del Rocio, Seville, Spain); M. Montejo (Hospital Universitario Cruces, Bilbao, Spain), E. Merino de Lucas (Hospital General Universitario de Alicante, Spain); B. M. Eriksson (Akademiska Hospital, Uppsala, Sweden); C. van Delden and O. Manuel on behalf of Swiss Transplant Cohort Study (STCS, Switzerland); H. Arsalan (Başkent University School Of Medicine, Ankara, Turkey); Z. Koçak Tufan (Yildirim Beyazit University, Ataturk T&H Hospital, Ankara, Turkey); E. Kazak (Uludag University, Bursa, Turkey); M. David (University Hospital Birmingham NHS Trust, Birmingham, United Kingdom); E. Lease (University of Washington, Seattle, USA); G. Cornaglia on behalf of ESGARS – ESCMID Study Group for Antimicrobial Resistance Surveillance; and M. Akova (Department of Infectious Diseases Hacettepe University School of Medicine Sihiyie, Ankara, Turkey).

This work was supported by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0008; RD16/0016/0001, RD16/0016/0002, RD16/0016/00010] - co-financed by European Development Regional Fund “A way to achieve Europe”, Operational program Intelligent Growth 2014-2020; ESCMID Study Group for Infections in Compromised Hosts [ESGICH grant to JMA]; Sociedad Andaluza de Trasplante de Órgano Sólido [SATOT grant to LMM]; ESCMID Study Group for Infections in Compromised Hosts [ESGICH grant to JMA]; Sociedad Andaluza de Trasplante de Órgano Sólido [SATOT grant to LMM]; ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS).

DISCLOSURE
The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. JTC reports grants for educational activities from Astellas, Angelini and Gilead and personal fees, nonfinancial support and grants from MSD and Pfizer, outside the submitted work; JRB reports personal fees from Merck; SM reports personal fees from Shionogi, outside the submitted work; ER reports grants and personal fees from Gilead and Pfizer.
and grants from Astellas and Merck, outside the submitted work; PAG reports grants from MSD and personal fees from MSD, Biotest, Angelini, Paratek, Gilead, Becton Dickinson, and Nordic Pharma, outside the submitted work. The other authors have no conflicts of interest to disclose.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from FIBICO (Fundación para la Investigación Biomédica de Córdoba). Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors with the permission of FIBICO.

ORCID
Elena Pérez-Nadales https://orcid.org/0000-0002-6796-1813
Mario Fernández-Ruiz https://orcid.org/0000-0002-0315-8001
Emmanuel Rolídes https://orcid.org/0000-0002-0202-364X
Álvaro Pascual https://orcid.org/0000-0002-8672-5891
Jesús Rodríguez-Baño https://orcid.org/0000-0001-6732-9001

REFERENCES
1. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–236.
2. van Duijn D, van Delden C. AST Infectious Diseases Community of Practice. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant. 2013;13:31–41.
3. Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58:1274–1283.
4. Aguado JM, Silva JT, Fernández-Ruiz M, et al. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev. 2018;32:36–57.
5. Carrara E, Bragantini D, Tacconelli E. Combination versus monotherapy for the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2018;31:1.
6. Bartoletti M, Giannella M, Tedeschi S, Viale P. Multidrug-resistant bacterial infections in solid organ transplant candidates and recipients. Infect Dis Clin North Am. 2018;32:551–580.
7. Pouch SM, Satlin MJ. Carbapenem-resistant enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence. 2017;8:391.
8. Macesic N, Gomez-Simmonds A, Sullivan SB, et al. Genomic surveillance reveals diversity of multidrug-resistant organism colonization and infection: a prospective cohort study in liver transplant recipients. Clin Infect Dis. 2018;67:905–912.
9. Cano A, Gutiérrez-Gutiérrez B, Machuca I, et al. Risks of infection and mortality among patients colonized with klebsiella pneumoniae carbapenemase-producing klebsiella pneumoniae: validation of scores and proposal for management. Clin Infect Dis. 2018;66:1204–1210.
10. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, Ampc-, and carbapenemase-producing enterobacteriaceae. Clin Microbiol Rev. 2018;31:e00079–e00117.
11. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17:726–734.
12. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing enterobacteriaceae. Mayo Clin Proc. 2016;91:1362–1371.
13. Machuca I, Gutiérrez-Gutiérrez B, Gracia-Ahufinger I, et al. Mortality associated with bacteremia due to colistin-resistant klebsiella pneumoniae with high-level meropenem resistance: importance of combination therapy without colistin and carbapenems. Antimicrob Agents Chemother. 2017;61:e00406–e00417.
14. von Elm E, Altman DG, Egger M, et al. The strengthening of reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370:1453–1457.
15. Barchiesi F, Montalti R, Castelli P, et al. Carbapenem-resistant klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients. BMC Infect Dis. 2016;16:538.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
17. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 1989;87:540–546.
18. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29(4):530–538.
19. Clinical and Laboratory Standards Institute, Wayne P. M100–S25 performance standards for antimicrobial susceptibility testing: twenty-fifth informational supplement. 2015.
20. Moreno A, Cervera C, Gavalda J, et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant. 2007;7:2579–2586.
21. Freire MP, Abdala E, Moura ML, et al. Risk factors and outcome of infections with Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in kidney transplant recipients. Infection. 2015;43:315–323.
22. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16:18.
23. Sousa A, Pérez-Rodríguez MT, Soto A, et al. Effectiveness of cef-tazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing enterobacteriaceae. J Antimicrob Chemother. 2018;73:3170–3175.
24. Li C, Li Y, Zhao Z, Liu Q, Li B. Treatment options and clinical outcomes of patients infected with carbapenem-resistant Klebsiella pneumoniae due to OXA-48 carbapenemase-producing enterobacteriaceae. J Infect Public Health. 2019;12:26–31.
25. Fishman JA. From the classic concepts to modern practice. Clin Microbiol Infect. 2014;20:4–9.
26. Bartoletti M, Vandi G, Furi F, et al. Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection. Transpl Infect Dis. 2018;20:e12930.
27. Torre-Cisneros J, Aguado JM, Caston JJ, et al. Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev. 2016;30:119–143.
28. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet. 2005;365:2105–2115.
29. Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus
in solid-organ transplantation. Transplantation. 2018;102:900–931.

30. Castón JJ, Cantisán S, González-Gasca F, et al. Interferon-γ production by CMV-specific CD8+ T lymphocytes provides protection against cytomegalovirus reactivation in critically ill patients. Intensive Care Med. 2016;42:46–53.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Pérez-Nadales E, Gutiérrez-Gutiérrez B, Natera AM, et al. Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. Am J Transplant. 2020;20:1629–1641. https://doi.org/10.1111/ajt.15769